Actively Recruiting
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Led by Kymera Therapeutics, Inc. · Updated on 2026-04-23
200
Participants Needed
61
Research Sites
131 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.
CONDITIONS
Official Title
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 12 and 75 years, inclusive, at the time of consent
- Chronic atopic dermatitis present for at least 3 years if 18 years or older, or at least 1 year if under 18
- Eczema Area and Severity Index (EASI) score of 16 or higher at Screening and Baseline visits
- Valid Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) score of 3 or higher at Screening and Baseline visits
- At least 10% body surface area affected by atopic dermatitis at Screening and Baseline visits
- Weekly average Peak Pruritus Numeric Rating Scale (NRS) value of 4 or higher at Baseline visit
- History within 6 months before Baseline of inadequate response to or inability to use topical medications for atopic dermatitis
- Use of a stable moisturizer dose at least twice daily for at least 7 consecutive days before Baseline and willingness to continue twice daily use during the study
- Ability and willingness to comply with scheduled visits, treatment plan, laboratory tests, procedures, and questionnaires including electronic diary completion
- Agreement to contraceptive requirements as per study and local guidelines
You will not qualify if you...
- Unstable course of atopic dermatitis (improving or worsening) within 4 weeks before Baseline
- Other skin conditions that might interfere with assessments, such as contact dermatitis, psoriasis, tinea corporis, or lupus erythematosus
- Clinically relevant history of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, endocrine, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, ophthalmological, or connective tissue diseases
- Planned surgical or medical procedures during the study
- History of alcohol or substance abuse within 2 years prior to the study
- Pregnancy, breastfeeding, or plans to become pregnant or breastfeed during the study
- Lack of response to medications targeting IL-4, IL-13, or JAK-STAT pathways after at least 16 weeks of therapy
- Abnormal clinical laboratory safety test results outside local reference ranges at Screening
- Use of investigational drugs or devices within 8 weeks or 5 half-lives before KT-621 administration
- Positive or undetermined pregnancy test at Screening and Baseline for females of childbearing potential
- Any factor that might interfere with treatment compliance, study conduct, or result interpretation
- Use of prohibited therapies within specified timeframes before study as assessed by Investigator
- Known sensitivity to any components of KT-621
- Membership in the investigational team or immediate family
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 61 locations
1
Kymera Investigative Site
Birmingham, Alabama, United States, 35244
Actively Recruiting
2
Kymera Investigative Site
North Little Rock, Arkansas, United States, 72117
Actively Recruiting
3
Kymera Investigative Site
Freemont, California, United States, 94538
Actively Recruiting
4
Kymera Investigative Site
Los Angeles, California, United States, 90025
Actively Recruiting
5
Kymera Investigative Site
Los Angeles, California, United States, 90045
Actively Recruiting
6
Kymera Investigative Site
Santa Monica, California, United States, 91350
Actively Recruiting
7
Kymera Investigative Site
Delray Beach, Florida, United States, 33484
Actively Recruiting
8
Kymera Investigative Site
Miami, Florida, United States, 33137
Actively Recruiting
9
Kymera Investigative Site
Miramar, Florida, United States, 33027
Actively Recruiting
10
Kymera Investigative Site
Normal, Illinois, United States, 61761
Actively Recruiting
11
Kymera Investigative Site
Indianapolis, Indiana, United States, 46202
Actively Recruiting
12
Kymera Investigative Site
Ann Arbor, Michigan, United States, 48103
Actively Recruiting
13
Kymera Investigative Site
Detroit, Michigan, United States, 48202
Actively Recruiting
14
Kymera Investigative Site
The Bronx, New York, United States, 10455
Actively Recruiting
15
Kymera Investigative Site
Fargo, North Dakota, United States, 58103
Actively Recruiting
16
Kymera Investigative Site
Portland, Oregon, United States, 97201
Actively Recruiting
17
Kymera Investigative Site
Portland, Oregon, United States, 97239
Actively Recruiting
18
Kymera Investigative Site
Philadelphia, Pennsylvania, United States, 19103
Actively Recruiting
19
Kymera Investigative Site
San Antonio, Texas, United States, 78213
Actively Recruiting
20
Kymera Investigative Site
San Antonio, Texas, United States, 78218
Actively Recruiting
21
Kymera Investigative Site
Darlinghurst, New South Wales, Australia
Actively Recruiting
22
Kymera Investigative Site
Kogarah, New South Wales, Australia
Actively Recruiting
23
Kymera Investigative Site
Brisbane, Queensland, Australia
Actively Recruiting
24
Kymera Investigative Site
Woolloongabba, Queensland, Australia
Actively Recruiting
25
Kymera Investigative Site
Melbourne, Victoria, Australia
Actively Recruiting
26
Kymera Investigative Site
Calgary, Alberta, Canada
Actively Recruiting
27
Kymera Investigative Site
Edmonton, Alberta, Canada
Actively Recruiting
28
Kymera Investigative Site
Kelowna, British Columbia, Canada
Actively Recruiting
29
Kymera Investigative Site
Surrey, British Columbia, Canada
Actively Recruiting
30
Kymera Investigative Site
Markham, Ontario, Canada
Actively Recruiting
31
Kymera Investigative Site
Ottawa, Ontario, Canada
Actively Recruiting
32
Kymera Investigative Site
Richmond Hill, Ontario, Canada
Actively Recruiting
33
Kymera Investigative Site
Toronto, Ontario, Canada
Actively Recruiting
34
Kymera Investigative Site
Québec, Quebec, Canada
Actively Recruiting
35
Kymera Investigative Site
Pardubice, Czechia
Actively Recruiting
36
Kymera Investigative Site
Prague, Czechia
Actively Recruiting
37
Kymera Investigative Site
Augsburg, Bavaria, Germany
Actively Recruiting
38
Kymera Investigative Site
München, Bavaria, Germany
Actively Recruiting
39
Kymera Investigative Site
Bad Bentheim, Germany
Actively Recruiting
40
Kymera Investigative Site
Berlin, Germany
Actively Recruiting
41
Kymera Investigative Site
Dresden, Germany
Actively Recruiting
42
Kymera Investigative Site
Mainz, Germany
Actively Recruiting
43
Kymera Investigative Site
Ichikawa, Chiba, Japan
Actively Recruiting
44
Kymera Investigative Site
Kagoshima, Japan
Actively Recruiting
45
Kymera Investigative Site
Kanagawa, Japan
Actively Recruiting
46
Kymera Investigative Site
Osaka, Japan
Actively Recruiting
47
Kymera Investigative Site
Sakai, Japan
Actively Recruiting
48
Kymera Investigative Site
Chorzów, Poland
Actively Recruiting
49
Kymera Investigative Site
Gdansk, Poland
Actively Recruiting
50
Kymera Investigative Site
Gdynia, Poland
Actively Recruiting
51
Kymera Investigative Site
Krakow, Poland
Actively Recruiting
52
Kymera Investigative Site
Lublin, Poland
Actively Recruiting
53
Kymera Investigative Site
Rzeszów, Poland
Actively Recruiting
54
Kymera Investigative Site
Szczecin, Poland
Actively Recruiting
55
Kymera Investigative Site
Warsaw, Poland
Actively Recruiting
56
Kymera Investigative Site
Wroclaw, Poland
Actively Recruiting
57
Kymera Investigative Site
Ansan-si, South Korea
Actively Recruiting
58
Kymera Investigative Site
Cheonan, South Korea
Actively Recruiting
59
Kymera Investigative Site
Gyeonggi-do, South Korea
Actively Recruiting
60
Kymera Investigative Site
Incheon, South Korea
Actively Recruiting
61
Kymera Investigative Site
Seoul, South Korea
Actively Recruiting
Research Team
K
Kymera Medical Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here